Clinical Trial Update: Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

View source ↗

Summary

The study provides long-term safety data for pirfenidone (Esbriet) in patients with idiopathic pulmonary fibrosis, reporting completed safety results from an ex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Esbriet (pirfenidone)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Pulmonary Fibrosis | Status: COMPLETED